Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Patients With HIV-1 Infection and Ongoing Substance Use Disorder: The BASE Study

BACKGROUND: People with human immunodeficiency virus (HIV) and substance use disorder (PWH/SUD) are at higher risk of nonadherence to antiretroviral therapy. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) exhibits high rates of efficacy with a favorable adverse event profile. The BASE stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Havens, Joshua P, Bares, Sara H, Lyden, Elizabeth, Podany, Anthony T, Scarsi, Kimberly K, Fadul, Nada, Swindells, Susan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003752/
https://www.ncbi.nlm.nih.gov/pubmed/36910693
http://dx.doi.org/10.1093/ofid/ofad080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003752/
https://www.ncbi.nlm.nih.gov/pubmed/36910693
http://dx.doi.org/10.1093/ofid/ofad080

Ejemplares similares